Skip to main content

Table 2 Clinical outcomes

From: The effect of dexmedetomidine on vasopressor requirements in patients with septic shock: a subgroup analysis of the Sedation Practice in Intensive Care Evaluation [SPICE III] Trial

Outcome DEX (n = 44) Usual care (n = 39) Estimate (95%CI) p value
Difference in medians
 NEq dosea, μg/kg/min 0.03 [0.01, 0.07] 0.04 [0.01, 0.16] − 0.01 [− 0.06, 0.04] 0.17
 Noradrenaline dosea, μg/kg/min 0.03 [0.01, 0.07] 0.05 [0.01, 0.15] − 0.01 [− 0.06, 0.03] 0.08
 Cumulative NEq dosea, μg/kg/48 h. 1.51 [0.51, 3.60] 2.14 [0.58, 7.78] − 0.62 [− 3.18, 1.93] 0.19
 Peak NEq dosea, μg/kg/min 0.12 [0.05, 0.20] 0.16 [0.08, 0.32] − 0.03 [− 0.12, 0.06] 0.24
 Change in NEq dose from baseline to peak levela, μg/kg/min 0.05 [0.01, 0.12] 0.05 [0.01, 0.14] − 0.01 [− 0.06, 0.05] 0.61
 Total duration of vasopressor supportb, h 51.6 [18.3, 99.7] 45.7 [19.6, 159.0] 3.1 [− 30.7, 36.9] 0.72
  Survivors (n = 67) 35.6 [18.3, 69.4] 40.3 [22.2, 75.6] − 3.5 [− 30.1, 23.1] 0.64
  Non-survivors (n = 16) 186.0 [59.0, 311.0] 70.4 [19.4, 168.0] 19.8 [− 173.1, 212.6] 0.42
 Duration of invasive ventilationb, days 2.2 [1.1, 5.9] 2.8 [1.2, 9.6] − 0.5 [− 3.8, 2.8] 0.60
 Hospital length of stayb, days 15.5 [9.4, 24.4] 13.2 [7.7, 21.0] − 2.2 [− 8.5, 4.1] 0.30
 ICU length of stayb, days 4.2 [2.7, 10.2] 4.7 [3.0, 11.3] − 0.4 [− 3.4, 2.6] 0.67
  Survivors (n = 67) 4.1 [3.0, 9.2] 4.3 [3.2, 7.0] − 0.1 [− 2.7, 2.3] 0.70
  Non-survivors (n = 16) 8.9 [2.4, 16.2] 8.3 [0.8, 11.3] − 3.3 [− 16.2, 9.6] 0.87
Odds ratio (95% CI)
 Patients alive and vasopressor-free at 48 h after randomization 20 (45.5) 18 (46.2) 0.97 (0.41–2.31) 0.95
 ICU mortality 6 (13.6) 10 (25.6) 0.46 (0.15–1.41) 0.17
 Hospital mortality 9 (20.5) 12 (30.8) 0.58 (0.21–1.57) 0.28
 Day 90 mortality 12 (27.3) 13 (34.2) 0.72 (0.28–1.85) 0.50
  1. Categorical values are expressed as numbers (%). Continuous variables are presented as medians [IQR]
  2. DEX dexmedetomidine, IQR interquartile range, 95% CI 95% confidence interval, ICU intensive care unit, MAP mean arterial pressure, NEq noradrenaline equivalents
  3. aIn the first 48 h after randomization
  4. bWithin principal hospital admission, measured from randomization